Skip Navigation LinksHome > May 2014 - Volume 24 - Issue 4 > Risk Factors for Ovarian Cancers With and Without Microsatel...
International Journal of Gynecological Cancer:
doi: 10.1097/IGC.0000000000000134
Ovarian Cancer

Risk Factors for Ovarian Cancers With and Without Microsatellite Instability

Segev, Yakir MD*†‡; Pal, Tuya MD; Rosen, Barry MD†‡; McLaughlin, John R. PhD§; Sellers, Thomas A. PhD; Risch, Harvey A. MD, PhD; Zhang, Shiyu PhD*; Sun, Ping PhD*; Narod, Steven A. MD, PhD*; Schildkraut, Joellen PhD#

Collapse Box

Abstract

Objective

In a population-based sample of epithelial ovarian cancers, the objective of this study was to evaluate the association between microsatellite instability (MSI) status and the following factors: (1) ovarian cancer risk factors and (2) the distribution of the specific histologic subtypes.

Patients and Methods

Participants were drawn from 3 population-based studies of primary epithelial ovarian cancer; tumor DNA was analyzed using 5 standardized microsatellite markers to assess the MSI status. Patients were divided into 3 groups (MSI-high, MSI-low, and MSI-stable) according to the National Cancer Institute criteria. We compared the prevalence of specific known risk and protective factors among the 3 subgroups, including body mass index, smoking history, parity, BRCA1 and BRCA2 mutation status, past oral contraceptive use, and tubal ligation. Similarly, we compared the distribution of the histologic subtypes among the 3 subgroups.

Results

A total of 917 ovarian cancer patients were included. One hundred twenty-seven cases of cancer (13.8%) were MSI-high. Subgroup analyses according to smoking, body mass index, parity, past oral contraceptive use, and past tubal ligation did not reveal any statistically significant differences among the groups. Among the 29 patients with BRCA1 mutations, 20.7% had MSI-high cancers compared with 5.9% among 17 patients with BRCA2 mutations. The proportions of different ovarian cancer histologies among the various MSI subgroups were similar.

Conclusions

The prevalence of risk and protective factors among ovarian cancer patients is similar for cancers with and without MSI. The distributions of MSI do not differ significantly among ovarian cancers with different histologies. Ovarian cancer patients with BRCA1 mutations had a 21% rate of MSI-high tumors compared with 6% among patients with BRCA2 mutations, but this difference was not statistically significant.

Copyright © 2014 by IGCS and ESGO

Login

Article Tools

Share

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.

Connect With Us

Twitter
twitter.com/IJGConline

For additional oncology content, visit LWW Oncology Journals on Facebook.